The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial. Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2010-01, Vol.12 (2), p.R63-R63, Article R63
Hauptverfasser:	Becker, Michael A, Schumacher, H Ralph, Espinoza, Luis R, Wells, Alvin F, MacDonald, Patricia, Lloyd, Eric, Lademacher, Christopher
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Allopurinol - therapeutic use Care and treatment Clinical trials Comorbidity Dose-Response Relationship, Drug Drug therapy Febuxostat Female Gout Gout - blood Gout - drug therapy Gout - epidemiology Gout Suppressants - therapeutic use Humans Hyperlipidemias - epidemiology Hypertension - epidemiology Hyperuricemia Hyperuricemia - blood Hyperuricemia - drug therapy Hyperuricemia - epidemiology Kidney Diseases - epidemiology Male Management Middle Aged Obesity - epidemiology Research article Thiazoles - therapeutic use Treatment Outcome United States - epidemiology Uric Acid - blood Uric acid metabolism Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial. Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg in moderate renal impairment). Endpoints included the proportion of all subjects with sUA
ISSN:	1478-6354 1478-6362 1478-6354
DOI:	10.1186/ar2978